Welcome to our dedicated page for Optimizerx news (Ticker: OPRX), a resource for investors and traders seeking the latest updates and insights on Optimizerx stock.
OptimizeRx Corporation (Nasdaq: OPRX) regularly issues news and updates about its healthcare technology platform, partnerships, and financial performance. Company press releases describe OptimizeRx as a healthcare technology company that helps life science brands reach and engage healthcare professionals (HCPs) and patients through AI-driven tools, point-of-care integrations, and proprietary audience data.
News items for OptimizeRx often cover collaborations with other data and media companies, such as integrations that connect its patented Micro-Neighborhood® audience data with external identity graphs or out-of-home advertising networks. These announcements explain how the company’s privacy-safe, deterministic audience cohorts are used to support omnichannel and direct-to-consumer campaigns, improve audience quality, and reduce audience loss during onboarding and activation.
Investors and observers will also find earnings releases and guidance updates among OptimizeRx news. These releases include discussions of revenue trends, profitability metrics, key performance indicators related to top pharmaceutical manufacturers, and commentary from management about the company’s progress toward its strategic objectives. Conference call announcements and investor conference participation are also common topics, providing details on how to access management’s discussions of quarterly and annual results.
Additional news highlights may include expansions of the company’s in-workflow point-of-care network through new or renewed agreements with electronic health record (EHR) vendors, e-prescribing platforms, and health systems access partners. Leadership updates and organizational changes are reported through current reports and associated press releases, outlining adjustments in executive roles and governance. For anyone following OPRX, this news page serves as a central source for official company communications on partnerships, technology developments, financial results, and corporate governance.
Summary not available.
OptimizeRx Corp (Nasdaq: OPRX) announces a conference call on May 4, 2022, at 4:30 p.m. Eastern Time to discuss its first-quarter financial results for the period ending March 31, 2022. A press release with the financial results will precede the call. Participants can join by telephone or webcast, with a replay available for 12 months on the company’s website. OptimizeRx provides point-of-care technology solutions, connecting healthcare providers and patients to enhance medication adherence.
Summary not available.
Summary not available.
Summary not available.
OptimizeRx has announced the acquisition of EvinceMed, enhancing its point-of-care technology solutions to improve access to specialty medications for patients. This strategic acquisition strengthens OptimizeRx's platform, which connects over 700,000 healthcare providers, enabling faster patient access to therapies through process automation. Specialty drugs, while only 2.2% of prescriptions, accounted for over 45% of pharmacy spending in 2019, highlighting a significant market opportunity. The integration aims to increase revenue growth in 2023 and improve workflows for healthcare providers.
OptimizeRx Corp (Nasdaq: OPRX) announced that its Senior VP of Corporate Finance, Andy D'Silva, will participate in the 34th Annual ROTH Conference from March 13-15, 2022, in Dana Point, CA. D'Silva will engage in one-on-one and small group meetings with investors on March 14-15. The conference includes discussions on various growth sectors, featuring approximately 400 companies. OptimizeRx connects over 60% of U.S. healthcare providers, facilitating patient engagement and therapy adherence through its technology platform.
OptimizeRx Corp. (Nasdaq: OPRX) reported a 24% increase in Q4 2021 revenues, reaching $20.3 million, with a gross profit margin of 61%. Full-year revenue rose 42% to $61.3 million. The company achieved a net income of $0.6 million in Q4, down from $1.4 million in the previous year, while non-GAAP net income improved to $4.0 million. The firm anticipates 2022 revenue between $80 million and $85 million, reflecting growth between 31% and 39%.
Summary not available.
OptimizeRx Corp (Nasdaq: OPRX) reported preliminary financial results for Q4 2021, anticipating revenues of approximately $20.3 million, marking a 42% increase year-over-year. The company achieved a GAAP net income of $0.6 million and a record adjusted EBITDA of $4.0 million. As part of its growth strategy, OptimizeRx introduced new KPIs focused on customer penetration within the top pharmaceutical manufacturers and aims for 2022 revenues between $80 million to $85 million, projecting 31% to 39% growth.